Jea Young Min1,2, Marie R Griffin1,2,3, Adriana M Hung1,2, Carlos G Grijalva1,3, Robert A Greevy1,4, Xulei Liu1,4, Tom Elasy1,2, Christianne L Roumie5,6. 1. Veterans Health Administration - Tennessee Valley Healthcare System Geriatrics Research Education Clinical Center (GRECC), Health Service Research and Development Center (HSRD), Nashville, TN, USA. 2. Department of Medicine, Vanderbilt University, Nashville, TN, USA. 3. Department of Health Policy, Vanderbilt University, Nashville, TN, USA. 4. Department of Biostatistics, Vanderbilt University, Nashville, TN, USA. 5. Veterans Health Administration - Tennessee Valley Healthcare System Geriatrics Research Education Clinical Center (GRECC), Health Service Research and Development Center (HSRD), Nashville, TN, USA. christianne.roumie@vanderbilt.edu. 6. Department of Medicine, Vanderbilt University, Nashville, TN, USA. christianne.roumie@vanderbilt.edu.
Abstract
BACKGROUND: Type 2 diabetes patients often initiate treatment with a sulfonylurea and subsequently intensify their therapy with insulin. However, information on optimal treatment regimens for these patients is limited. OBJECTIVE: To compare risk of cardiovascular disease (CVD) and hypoglycemia between sulfonylurea initiators who switch to or add insulin. DESIGN: This was a retrospective cohort assembled using national Veterans Health Administration (VHA), Medicare, and National Death Index databases. PARTICIPANTS: Veterans who initiated diabetes treatment with a sulfonylurea between 2001 and 2008 and intensified their regimen with insulin were followed through 2011. MAIN MEASURES: The association between insulin versus sulfonylurea + insulin and time to CVD or hypoglycemia were evaluated using Cox proportional hazard models in a 1:1 propensity score-matched cohort. CVD included hospitalization for acute myocardial infarction or stroke, or cardiovascular mortality. Hypoglycemia included hospitalizations or emergency visits for hypoglycemia, or outpatient blood glucose measurements <60 mg/dL. Subgroups included age < 65 and ≥ 65 years and estimated glomerular filtration rate ≥ 60 and < 60 ml/min. KEY FINDINGS: There were 1646 and 3728 sulfonylurea monotherapy initiators who switched to insulin monotherapy or added insulin, respectively. The 1596 propensity score-matched patients in each group had similar baseline characteristics at insulin initiation. The rate of CVD per 1000 person-years among insulin versus sulfonylurea + insulin users were 49.3 and 56.0, respectively [hazard ratio (HR) 0.85, 95 % confidence interval (CI) 0.64, 1.12]. Rates of first and recurrent hypoglycemia events per 1000 person-years were 74.0 and 100.0 among insulin users compared to 78.9 and 116.8 among sulfonylurea plus insulin users, yielding HR (95 % CI) of 0.94 (0.76, 1.16) and 0.87 (0.69, 1.10), respectively. Subgroup analysis results were consistent with the main findings. CONCLUSIONS: Compared to sulfonylurea users who added insulin, those who switched to insulin alone had numerically lower CVD and hypoglycemia events, but these differences in risk were not statistically significant.
BACKGROUND:Type 2 diabetespatients often initiate treatment with a sulfonylurea and subsequently intensify their therapy with insulin. However, information on optimal treatment regimens for these patients is limited. OBJECTIVE: To compare risk of cardiovascular disease (CVD) and hypoglycemia between sulfonylurea initiators who switch to or add insulin. DESIGN: This was a retrospective cohort assembled using national Veterans Health Administration (VHA), Medicare, and National Death Index databases. PARTICIPANTS: Veterans who initiated diabetes treatment with a sulfonylurea between 2001 and 2008 and intensified their regimen with insulin were followed through 2011. MAIN MEASURES: The association between insulin versus sulfonylurea + insulin and time to CVD or hypoglycemia were evaluated using Cox proportional hazard models in a 1:1 propensity score-matched cohort. CVD included hospitalization for acute myocardial infarction or stroke, or cardiovascular mortality. Hypoglycemia included hospitalizations or emergency visits for hypoglycemia, or outpatientblood glucose measurements <60 mg/dL. Subgroups included age < 65 and ≥ 65 years and estimated glomerular filtration rate ≥ 60 and < 60 ml/min. KEY FINDINGS: There were 1646 and 3728 sulfonylurea monotherapy initiators who switched to insulin monotherapy or added insulin, respectively. The 1596 propensity score-matched patients in each group had similar baseline characteristics at insulin initiation. The rate of CVD per 1000 person-years among insulin versus sulfonylurea + insulin users were 49.3 and 56.0, respectively [hazard ratio (HR) 0.85, 95 % confidence interval (CI) 0.64, 1.12]. Rates of first and recurrent hypoglycemia events per 1000 person-years were 74.0 and 100.0 among insulin users compared to 78.9 and 116.8 among sulfonylurea plus insulin users, yielding HR (95 % CI) of 0.94 (0.76, 1.16) and 0.87 (0.69, 1.10), respectively. Subgroup analysis results were consistent with the main findings. CONCLUSIONS: Compared to sulfonylurea users who added insulin, those who switched to insulin alone had numerically lower CVD and hypoglycemia events, but these differences in risk were not statistically significant.
Authors: R A Greevy; M M Huizinga; C L Roumie; C G Grijalva; H Murff; X Liu; M R Griffin Journal: Clin Pharmacol Ther Date: 2011-11-02 Impact factor: 6.875
Authors: Silvio E Inzucchi; Richard M Bergenstal; John B Buse; Michaela Diamant; Ele Ferrannini; Michael Nauck; Anne L Peters; Apostolos Tsapas; Richard Wender; David R Matthews Journal: Diabetes Care Date: 2015-01 Impact factor: 19.112
Authors: Denise M Hynes; Kristin Koelling; Kevin Stroupe; Noreen Arnold; Katherine Mallin; Min-Woong Sohn; Frances M Weaver; Larry Manheim; Linda Kok Journal: Med Care Date: 2007-03 Impact factor: 2.983
Authors: M Alvarsson; G Sundkvist; I Lager; K Berntorp; E Fernqvist-Forbes; L Steen; T Orn; M A Holberg; N Kirksaether; V Grill Journal: Diabetes Obes Metab Date: 2007-03-29 Impact factor: 6.577
Authors: Stephen S Johnston; Christopher Conner; Mark Aagren; David M Smith; Jonathan Bouchard; Jason Brett Journal: Diabetes Care Date: 2011-03-18 Impact factor: 19.112
Authors: Silvio E Inzucchi; Richard M Bergenstal; John B Buse; Michaela Diamant; Ele Ferrannini; Michael Nauck; Anne L Peters; Apostolos Tsapas; Richard Wender; David R Matthews Journal: Diabetes Care Date: 2012-04-19 Impact factor: 19.112
Authors: Kunihiro Matsushita; Bakhtawar K Mahmoodi; Mark Woodward; Jonathan R Emberson; Tazeen H Jafar; Sun Ha Jee; Kevan R Polkinghorne; Anoop Shankar; David H Smith; Marcello Tonelli; David G Warnock; Chi-Pang Wen; Josef Coresh; Ron T Gansevoort; Brenda R Hemmelgarn; Andrew S Levey Journal: JAMA Date: 2012-05-09 Impact factor: 56.272
Authors: Jea Young Min; Caroline A Presley; Jennifer Wharton; Marie R Griffin; Robert A Greevy; Adriana M Hung; Jonathan Chipman; Carlos G Grijalva; Amber J Hackstadt; Christianne L Roumie Journal: Pharmacoepidemiol Drug Saf Date: 2019-03-06 Impact factor: 2.890
Authors: Katherine N Bachmann; Christianne L Roumie; Andrew D Wiese; Carlos G Grijalva; John B Buse; Robert Bradford; Emily O Zalimeni; Patricia Knoepp; Sofia Dard; Heather L Morris; William T Donahoo; Nada Fanous; Vivian Fonseca; Bonnie Katalenich; Sujung Choi; Darcy Louzao; Emily O'Brien; Megan M Cook; Russell L Rothman; Rosette J Chakkalakal Journal: Pharmacol Res Perspect Date: 2020-10